Skip to content
Menu

Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $130

Benzinga Newsdesk 10 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $215 to $130.

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $215 to $130.

Read at benzinga.com